PRNewsWire
01 Aug 2026, 02:00 UTC · 11w ago
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Impact · against what's priced in
ADMA Biologics faces significant downward pressure due to class action allegations of channel stuffing and systemic internal control failures. Humacyte is also under investigation for potential securities law violations, introducing governance risks to both companies.
- ADMA−0.80
No priced-in read yet





